Prot #AG881-C-004: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/207/1/23

Funding

  • DrugDev Inc. (Prot #AG881-C-004)
  • Agios Pharmaceuticals, Inc. (Prot #AG881-C-004)